Journey Medical Corporation (NASDAQ: DERM) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $110M. The Maz Rating grades it against the other companies in its sector.
Journey Medical Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $3.90, Journey Medical Corporation trades at 1.5x sales and 3.1x book value, with an EV/EBITDA of 40.4. Over the last twelve months it generated about $75M of revenue and a net loss of $6M. It runs a gross margin of 43.2%, an operating margin of -2.9% and a net margin of -7.3%. It shows return on equity of -16.1%, return on invested capital of -3.5% and a free cash flow yield of -8.0%. On the balance sheet: a debt-to-equity ratio of 0.79 and a current ratio of 1.48. Over the past 52 weeks the share price ranged from $3.40 to $9.56, with a beta of 1.15.
Journey Medical Corporation does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Journey Medical Corporation (DERM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 15.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 13.2% / 30% · Interest income / Revenue 0.74% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 15.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.2% / 33% · Receivables / Mkt Cap (36m) 28.0% / 49% · Interest income / Revenue 0.74% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 15.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.2% / 33.33% · Receivables / Mkt Cap (24m) 28.0% / 33.33% · Interest income / Revenue 0.74% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 26.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 25.6% / 33.33% · Receivables / Avg Assets (4Q) 35.6% / 33.33% · Interest income / Revenue 0.74% / 5% | Fail |
| FTSE | Debt / Total Assets 24.7% / 33.33% · (Cash+ST Inv) / Total Assets 21.5% / 33.33% · (Cash+Recv) / Total Assets 67.1% / 33.33% · Interest income / Revenue 0.74% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Journey Medical Corporation (DERM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Journey Medical Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.74% of each dividend: Journey Medical Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.